In this context, asparaginase (ASNase) is part of polychemotherapy regimens used for B-ALL treatment [82,83] and in advanced phase clinical trials for other hematological malignancies, such as actute myeloid leukemia (AML) and T-ALL (Table 1). This evidence concerns the gene ASPG and acute lymphoblastic leukemia.